Your browser is old and is not supported. Upgrade for better security.

OncoSynergy

Platform drugs for orphan diseases like Cancer and Ebola


What Friends Say

M. Sean Grady, MD Chairman and Professor of Neurosurgery, University of Pennsylvania School of Medicine
OS2966 is an innovative new platform drug for the treatment of aggressive cancers including glioblastoma, the deadliest of all brain malignancies. The data they have produced demonstrating dramatic efficacy in therapy resistant cancers is particularly encouraging.
Judith M. White, PhD Leading Ebola scientist
The ongoing West African outbreak underscores the grave need for new approaches to treatment of Ebola Virus Disease. OS2966 is a unique host-directed experimental therapy unlike any other in development.
Thomas Geisbert, PhD Professor of Microbiology and Immunology
Ebola is deadly largely due to the body's own responses to the virus including overactive immune response and widespread clotting. OS2966 is a novel experimental drug in development for Ebola that can potentially block viral entry as well as multiple dysregulated host responses at the same time.

In the news

FDA Grants Orphan Drug Designation to OS2966 in the Treatment of Ovarian Cancer
January 21, 2015
ncoSynergy announced today that the FDA Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation for OS2966 in the treatment of ovarian cancer. The investigational drug candidate also received orphan designation for glioblastoma last summer.
Thomas W. Geisbert
August 23, 2014
Thomas W. Geisbert is a virologist who specializes in viral hemorrhagic fevers such as the Ebola virus. He and his team at the University of Texas Medical Branch in Galveston are currently working on developing vaccines to treat these diseases, which have mortality rates as high as 90 percent.
Ebola finds a new foe in crowd-funded startup
August 22, 2014
Yet San Francisco-based OncoSynergy, created after founder Dr. Shawn Carbonell dropped out of neuroscience residency at Cedars-Sinai Medical Center in Los Angeles, might have an inroad to a potential ebola treatment. Its experimental cancer drug, called OS-2966, is thought to inhibit a protein that is fundamental for progression of aggressive tumors like brain and ovarian cancer and, the company said, appears to be hijacked by the ebola virus during infection.
Science Exchange Stories: OncoSynergy, fighting brain cancer as the family business
January 21, 2014
To put it in his words, “When I found out she was single and was no longer in neurosurgery I made it my mission to both marry her and hire her. Last month both became reality.”
CMC Biologics, OncoSynergy Make Pact to Develop Materials for Toxicology Studies
December 17, 2013
CMC Biologics has inked an agreement with biotech start-up OncoSynergy to develop cell lines and for process development, analytical development, and manufacturing of both non-GMP material for early toxicology testing and cGMP material for IND-enabling toxicology studies and Phase I clinical trials. This work, the firms say, will advance OncoSynergy's OS2966 mAb program.
Science Exchange Stories: Shawn Carbonell, Brain Surgery Dropout
November 13, 2013
Although he had spent the last 18 years prepping for a career as an academic neurosurgeon, he couldn’t stop thinking about an idea he had that could help fight cancer. He had many options available to him, but he risked it all because he wanted to get a drug to the clinic in the quickest way possible.
What People Say